David Andrew Siesel

This inventor holds 22 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 11 EPO patents, primarily in Cystic Fibrosis Modulators. Top assignees: Vertex Pharmaceuticals, Inc., Novartis Vaccines & Diagnostics, Gmbh. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Andrew Siesel. Retrieved from https://idiyas.com/inventor/david-andrew-siesel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 6)

% Patents Active = 90.9

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 11 (Patent Applications = 15)

Average Co-Inventor Count = 3.0

ph-index = 13

Forward Citations = 615(Granted Patents)

Company Filing History:

21 out of 1,167

Vertex Pharmaceuticals, Inc.

patents

1 out of 245

Novartis Vaccines & Diagnostics, Gmbh

patents

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

Cystic Fibrosis

Modulators

ATR Inhibitors

Pharmaceutical Compositions

Treatment Methods

Cycloalkylcarboxamido Compounds

Benzimidazoles

Kinase Inhibitors

Processes for Preparation

Chemical Synthesis

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12415798 - Processes for making modulators of cystic fibrosis transmembrane conductance regulator (2025-09-16),

2. 12384762 - Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2025-08-12),

3. 12122788 - Process of making CFTR modulators (2024-10-22),

4. 11584761 - Process of making CFTR modulators (2023-02-21),

5. 11465985 - Processes for making modulators of cystic fibrosis transmembrane conductance regulator (2022-10-11),

6. 11453655 - Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2022-09-27),

7. 10822331 - Processes for preparing ATR inhibitors (2020-11-03),

8. 10793547 - Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2020-10-06),

9. 10570115 - Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2020-02-25),

10. 10208027 - Processes for preparing ATR inhibitors (2019-02-19),

11. 10071979 - Process of producing cycloalkylcarboxamido-indole compounds (2018-09-11),

12. 9862709 - Processes for making compounds useful as inhibitors of ATR kinase (2018-01-09),

13. 9776968 - Processes for producing cycloalkylcarboxamido-pyridine benzoic acids (2017-10-03),

14. 9035072 - Process of producing cycloalkylcarboxamido-indole compounds (2015-05-19),

15. 9035053 - Processes for making compounds useful as inhibitors of ATR kinase (2015-05-19),

Title: David Andrew Siesel - Innovative Inventor from San Diego

Introduction: David Andrew Siesel is a renowned inventor based in San Diego, California, known for his groundbreaking contributions to various industries.

Latest Patents: David Andrew Siesel holds several patents in the fields of technology, healthcare, and consumer products, showcasing his diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, David Andrew Siesel has consistently pushed the boundaries of innovation, leading to the development of cutting-edge solutions that have revolutionized the way we live and work.

Collaborations: Throughout his career, David Andrew Siesel has collaborated with leading companies, research institutions, and universities to bring his inventions to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: David Andrew Siesel's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and entrepreneurs.

Profile summary based on public USPTO records.